Bronchogen
Bronchogen (Ala-Asp-Glu-Leu) is a synthetic Khavinson bioregulator peptide marketed for respiratory/bronchial support. Evidence is limited to preclinical and Russian reports from the originating group; no independent human trials exist.
01 Overview
Bronchogen is a tetrapeptide bioregulator claimed to target bronchial and lung tissue, positioned for chronic bronchitis and respiratory recovery. Developer-group studies report effects on bronchial epithelium and inflammation in animal models.\n\nNo independent controlled human trials substantiate the respiratory claims. It is sold as a research peptide, typically intranasal or injectable.
02 Mechanism
Proposed tissue-specific regulation of bronchial epithelial gene expression, reducing inflammation and supporting repair; unverified in humans.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal | 100–200 mcg/day | Insufflated | Short cycled courses per vendor protocols; no clinical basis. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Bronchial anti-inflammatory supportReported effects on bronchial inflammation in animal models. | n/a | Preclinical | |
| Respiratory recovery claimMarketed for chronic bronchitis; unverified in humans. | n/a | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Nasal/mucosal irritationIntranasal peptide sprays can irritate nasal mucosa. | Mild | Common | Anecdotal | |
| Delay of respiratory diagnosisSelf-treating respiratory symptoms may delay diagnosis of asthma, COPD or infection. | Moderate | Situational | Unconfirmed |